Phosphoproteomics predict response to midostaurin plus chemotherapy in independent cohorts of FLT3-mutated acute myeloid leukaemiaResearch in context

Phosphoproteomics predict response to midostaurin plus chemotherapy in independent cohorts of FLT3-mutated acute myeloid leukaemiaResearch in context

Summary: Background: Acute myeloid leukaemia (AML) is a bone marrow malignancy with poor prognosis. One of several treatments for AML is midostaurin combined with intensive chemotherapy (MIC), currently approved for FLT3 mutation-positive (FLT3-MP) AML. However, many patients carrying FLT3 mutation...

Full description

Bibliographic Details
Main Authors: Weronika E. Borek, Luis Nobre, S. Federico Pedicona, Amy E. Campbell, Josie A. Christopher, Nazrath Nawaz, David N. Perkins, Pedro Moreno-Cardoso, Janet Kelsall, Harriet R. Ferguson, Bela Patel, Paolo Gallipoli, Andrea Arruda, Alex J. Ambinder, Andrew Thompson, Andrew Williamson, Gabriel Ghiaur, Mark D. Minden, John G. Gribben, David J. Britton, Pedro R. Cutillas, Arran D. Dokal
Format: Article
Language:English
Published: Elsevier 2024-10-01
Series:EBioMedicine
Subjects:
Phosphoproteomics
Machine learning
Precision medicine
Drug response prediction
Midostaurin plus chemotherapy
Acute myeloid leukaemia
Online Access:http://www.sciencedirect.com/science/article/pii/S2352396424003529

Internet

http://www.sciencedirect.com/science/article/pii/S2352396424003529

Similar Items